Benign neoplasm of other major salivary glands
ICD-10 D11.7 is a billable code used to indicate a diagnosis of benign neoplasm of other major salivary glands.
Benign neoplasms of the salivary glands are non-cancerous tumors that can arise in the major salivary glands, which include the parotid, submandibular, and sublingual glands, as well as other minor salivary glands. These neoplasms can present as painless swellings and may be discovered incidentally during imaging studies or physical examinations. Common types of benign salivary gland tumors include pleomorphic adenomas, Warthin's tumors, and oncocytomas. Although these tumors are generally not life-threatening, they can cause discomfort, functional impairment, or cosmetic concerns depending on their size and location. Surveillance for benign neoplasms is essential, as there is a small risk of malignant transformation, particularly in long-standing cases. Regular follow-up with imaging and clinical evaluation is recommended to monitor for any changes in size or characteristics that may suggest malignancy. Surgical excision is often the treatment of choice, especially if the tumor is symptomatic or shows signs of growth. Accurate coding for benign neoplasms is crucial for appropriate management and reimbursement.
Detailed descriptions of the tumor's size, location, and histological type are essential.
Evaluation of a patient with a palpable mass in the salivary gland region.
Ensure that imaging studies and biopsy results are included in the documentation.
Histopathological reports must clearly indicate the benign nature of the neoplasm.
Review of biopsy specimens from salivary gland masses.
Accurate reporting of tumor type and differentiation is critical for coding.
Used when a patient undergoes surgical removal of a benign salivary gland tumor.
Operative reports must detail the procedure and confirm the benign nature of the tumor.
Otolaryngologists should ensure that pre-operative imaging and pathology reports are included.
The most common types include pleomorphic adenomas, Warthin's tumors, and oncocytomas. Each type has distinct histological features and clinical implications.
Patients should undergo regular follow-up evaluations, typically every 6 to 12 months, to monitor for any changes in the size or characteristics of the neoplasm.
